Cesca Therapeutics I (KOOL) 3.50 $KOOL
Cesca Therapeutics to Exhibit at 14th International Cord Blood Symposium
GlobeNewswire - Wed Jun 08, 5:05AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that the Company will be exhibiting at the 14 International Cord Blood Symposium (ICBS), being held June 9-11 at the Hyatt Regency Hotel in San Francisco, California. As a leader in concentrating and cryopreserving stem cells from cord blood, Cesca is proud to sponsor the event.
KOOL: 3.50 (-0.17)
Cesca Therapeutics to Present at the LD Micro Invitational Conference
GlobeNewswire - Mon Jun 06, 5:05AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that Mr. Michael Bruch, the Company's Chief Financial Officer and Dalip Sethi, Ph.D., Clinical Research Director, will discuss recent corporate developments and initiatives at the LD Micro Invitational, being held June 7 - 9, 2016 at the Luxe Sunset Hotel in Los Angeles.
KOOL: 3.50 (-0.17)
Cesca Therapeutics Submits Investigational Device Exemption Supplement for SurgWerks(TM) CLI Pivotal Trial
GlobeNewswire - Wed Jun 01, 10:15AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that the Company has submitted an Investigational Device Exemption (IDE) Supplement to the U.S. Food and Drug Administration (FDA) for its previously approved pivotal trial for the treatment of patients with critical limb ischemia (CLI), using the Company's SurgWerks system. The Company expects the FDA to submit its response to the IDE supplement within 30 days of submission.
KOOL: 3.50 (-0.17)
Cesca Therapeutics to Exhibit at the 2016 International Society for Cellular Therapy Annual Meeting
GlobeNewswire - Tue May 24, 5:00AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that the Company will be exhibiting at the 2016 International Society for Cellular Therapy (ISCT) Annual Meeting in Booth B06 on May 25-28, 2016 at the Suntec Convention and Exhibition Center in Suntec City, Singapore.
KOOL: 3.50 (-0.17)
Cesca Therapeutics to Review Recent Corporate Milestones at the Marcum MicroCap Conference
GlobeNewswire - Fri May 20, 5:00AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that the Company's management team including, Mr. Robin Stracey, Chief Executive Officer, Mr. Michael Bruch, Chief Financial Officer and Dalip Sethi, Ph.D., Clinical Research Director, will discuss recent corporate developments and initiatives at the Marcum MicroCap Conference, which is being held June 1 - 2, 2016 at the Grand Hyatt Hotel in New York City.
KOOL: 3.50 (-0.17)
4 Stocks to Watch on Thursday May 19
ACCESSWIRE - Thu May 19, 1:02PM CDT
CORAL GABLES, FL / ACCESSWIRE / May 19, 2016 / TechStockInsider.com issues the following report: Today is an historic day in the market. It marks the anniversary of The Dow Jones Industrial Average having a record close of 18,312.39. But despite this very positive high in market history, investors have been hit with a rocky trading session on Thursday morning. This has left many, searching for stocks that have found an uptrend and we have been able to identify four stocks that investors are buying up on May 19.
KOOL: 3.50 (-0.17), PRGN: 0.73 (-0.03), GLBS: 0.55 (-0.04)
Cesca Therapeutics Announces Publication of a Case Report on Use of Its Technology for Treatment of Acute Myocardial Infarction
GlobeNewswire - Thu May 19, 5:00AM CDT
Data highlights promising results obtained from the AMIRST pilot study.
KOOL: 3.50 (-0.17)
Cesca Therapeutics Reports Third Quarter Fiscal 2016 Results and Provides Business Update
GlobeNewswire - Thu May 12, 3:37PM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today reported financial results for the third quarter of fiscal 2016 and provided an update to investors that included the status of clinical initiatives, with a particular emphasis on the Company's critical limb ischemia (CLI) program. The Company expects to submit an Investigational Device Exemption (IDE) supplement to the FDA at the end of the month detailing a range of changes to the pivotal CLI trial design and amendments to its CLI study protocol. The supplement will touch on, among other things, study end-points, the statistical analysis plan, the required patient enrollment totals for both the treatment arm and the control arm, patient inclusion/exclusion criteria and protocol changes designed to enhance patient enrollment.
KOOL: 3.50 (-0.17)
Cesca Reports Data From Six CLI Compassionate Use Patients Treated With SurgWerks(TM) Procedures at Fortis Escorts Heart Institute in New Delhi
GlobeNewswire - Wed May 11, 5:00AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced the results of six late-stage critical limb ischemia (CLI) patients treated with its SurgWerks(TM)-CLI system on a compassionate use basis. In a six-month follow-up of the patients, they reported favorable outcomes in lifestyle and pain reduction. The procedures were conducted by Dr. Suhail Bukhari of the Fortis Escorts Heart Institute and Research Center in New Delhi, India.
KOOL: 3.50 (-0.17)
Cesca Therapeutics to Report Third Quarter Fiscal 2016 Results on May 12, 2016
GlobeNewswire - Mon May 09, 5:00PM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that it will report financial results for the fiscal third quarter ended March 31, 2016 and provide a status update to investors on Thursday, May 12, 2016.
KOOL: 3.50 (-0.17)
Cesca Therapeutics To Present A Poster At The 2016 Annual Meeting Of The European Society For Blood And Bone Marrow Transplantation
GlobeNewswire - Thu Mar 31, 5:05AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that the Company will present a poster titled "Volume Reduction and RBC Depletion of Apheresis Products for Transplant" at the 42 Annual Meeting of the European Society for Blood and Bone Marrow Transplantation (EBMT) to be held in Valencia, Spain on April 3 - 6, 2016.
KOOL: 3.50 (-0.17)
Cesca Therapeutics' Indian Subsidiary Expands Cord Blood Banking Services To Additional Hospitals In The Fortis Healthcare Network
GlobeNewswire - Wed Mar 30, 5:05AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that its wholly-owned subsidiary in India, TotipotentRX, has expanded its private cord blood banking services into several hospitals within the Fortis Healthcare network in South and West India.
KOOL: 3.50 (-0.17)
Cesca Therapeutics Appoints Vascular Surgery Expert Lars Norgren, M.D., Ph.D., to its Clinical Advisory Board
GlobeNewswire - Wed Mar 23, 5:05AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that Dr. Lars Norgren, MD, Ph.D has joined its Clinical Advisory Board.
KOOL: 3.50 (-0.17)
Cesca Therapeutics to Present at the ARM 4th Annual Cell & Gene Therapy Investor Day
GlobeNewswire - Wed Mar 16, 5:05AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that Mike Bruch, Cesca Therapeutics' Chief Financial Officer, will present at the Alliance for Regenerative Medicine's 4 Annual Cell & Gene Therapy Investor Day on March 22, 2016, which will be held at the Metropolitan Club in New York City.
KOOL: 3.50 (-0.17)
Cesca Therapeutics Appoints Dr. Xiaochun Xu, Chairman and CEO of Boyalife Group, to Board of Directors
GlobeNewswire - Thu Mar 10, 5:05AM CST
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that Dr Xiaochun Xu (44) has been appointed to the Company's Board of Directors.
KOOL: 3.50 (-0.17)
Cesca Therapeutics Announces 1-for-20 Reverse Split of Common Stock
GlobeNewswire - Fri Mar 04, 3:05PM CST
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, has amended its Certificate of Incorporation to reflect a 1-for-20 reverse stock split effective 5:00pm PST on March 4, 2016.
KOOL: 3.50 (-0.17)
Texas Stem Cell Enters Into an Agreement With Cesca Therapeutics for Use of AutoXpress(R) Technology for Cord Blood Processing
GlobeNewswire - Tue Feb 09, 5:00AM CST
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that Texas Stem Cell has committed to utilizing Cesca's AutoXpress(R) AXP technology for its cord blood banking business. The AXP platform includes a 'smart' processing device and sterile disposable that automatically concentrates the stem cells from a cord blood unit in less than one hour and delivers them directly into Cesca's patented sample bag which is optimized for cryopreservation and storage. Cesca's AXP technology is widely used in cord blood banks around the world and has been referenced in dozens of clinical publications. Recently, clinical focus on cord blood has expanded due to the emergence of protocols enabling the expansion of cord blood cells in vitro, for subsequent therapeutic use in treatments for many forms of blood cancers including leukemia and lymphomas.
KOOL: 3.50 (-0.17)
Cell Therapy Industry: The Roads to Commercial Success
ACCESSWIRE - Wed Feb 03, 8:15AM CST
REDONDO BEACH, CA / ACCESSWIRE / February 3, 2016 / A recent panel discussion at the Alliance for Regenerative Medicine State of the Industry Briefing (associated with Biotech Showcase 2016 in San Francisco) raised the issue of bio-manufacturing scale up for cell therapies as a great need for continued development (see webcast here: http://alliancerm.org/event/regenerative-medi...-briefing). Among representatives of large pharmaceutical companies, or biotech companies partnered for development with large pharmaceutical companies, there was a general consensus that scaling up manufacturing for production of cell therapeutics was still a work in progress, and after nearly a decade of investment, more expertise and new technologies were required prior to commercialization.
KOOL: 3.50 (-0.17), MESO: 7.07 (+0.16), PFE: 35.29 (-0.02), CLLS: 29.48 (-1.53), NVS: 78.94 (-1.57)
Cesca Therapeutics to Exhibit at 14th International Cord Blood Symposium
GlobeNewswire - Wed Jun 08, 5:05AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that the Company will be exhibiting at the 14 International Cord Blood Symposium (ICBS), being held June 9-11 at the Hyatt Regency Hotel in San Francisco, California. As a leader in concentrating and cryopreserving stem cells from cord blood, Cesca is proud to sponsor the event.
KOOL: 3.50 (-0.17)
Cesca Therapeutics to Present at the LD Micro Invitational Conference
GlobeNewswire - Mon Jun 06, 5:05AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that Mr. Michael Bruch, the Company's Chief Financial Officer and Dalip Sethi, Ph.D., Clinical Research Director, will discuss recent corporate developments and initiatives at the LD Micro Invitational, being held June 7 - 9, 2016 at the Luxe Sunset Hotel in Los Angeles.
KOOL: 3.50 (-0.17)
Cesca Therapeutics Submits Investigational Device Exemption Supplement for SurgWerks(TM) CLI Pivotal Trial
GlobeNewswire - Wed Jun 01, 10:15AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that the Company has submitted an Investigational Device Exemption (IDE) Supplement to the U.S. Food and Drug Administration (FDA) for its previously approved pivotal trial for the treatment of patients with critical limb ischemia (CLI), using the Company's SurgWerks system. The Company expects the FDA to submit its response to the IDE supplement within 30 days of submission.
KOOL: 3.50 (-0.17)
Cesca Therapeutics to Exhibit at the 2016 International Society for Cellular Therapy Annual Meeting
GlobeNewswire - Tue May 24, 5:00AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that the Company will be exhibiting at the 2016 International Society for Cellular Therapy (ISCT) Annual Meeting in Booth B06 on May 25-28, 2016 at the Suntec Convention and Exhibition Center in Suntec City, Singapore.
KOOL: 3.50 (-0.17)
Cesca Therapeutics to Review Recent Corporate Milestones at the Marcum MicroCap Conference
GlobeNewswire - Fri May 20, 5:00AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that the Company's management team including, Mr. Robin Stracey, Chief Executive Officer, Mr. Michael Bruch, Chief Financial Officer and Dalip Sethi, Ph.D., Clinical Research Director, will discuss recent corporate developments and initiatives at the Marcum MicroCap Conference, which is being held June 1 - 2, 2016 at the Grand Hyatt Hotel in New York City.
KOOL: 3.50 (-0.17)
4 Stocks to Watch on Thursday May 19
ACCESSWIRE - Thu May 19, 1:02PM CDT
CORAL GABLES, FL / ACCESSWIRE / May 19, 2016 / TechStockInsider.com issues the following report: Today is an historic day in the market. It marks the anniversary of The Dow Jones Industrial Average having a record close of 18,312.39. But despite this very positive high in market history, investors have been hit with a rocky trading session on Thursday morning. This has left many, searching for stocks that have found an uptrend and we have been able to identify four stocks that investors are buying up on May 19.
KOOL: 3.50 (-0.17), PRGN: 0.73 (-0.03), GLBS: 0.55 (-0.04)
Cesca Therapeutics Announces Publication of a Case Report on Use of Its Technology for Treatment of Acute Myocardial Infarction
GlobeNewswire - Thu May 19, 5:00AM CDT
Data highlights promising results obtained from the AMIRST pilot study.
KOOL: 3.50 (-0.17)
Cesca Therapeutics Reports Third Quarter Fiscal 2016 Results and Provides Business Update
GlobeNewswire - Thu May 12, 3:37PM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today reported financial results for the third quarter of fiscal 2016 and provided an update to investors that included the status of clinical initiatives, with a particular emphasis on the Company's critical limb ischemia (CLI) program. The Company expects to submit an Investigational Device Exemption (IDE) supplement to the FDA at the end of the month detailing a range of changes to the pivotal CLI trial design and amendments to its CLI study protocol. The supplement will touch on, among other things, study end-points, the statistical analysis plan, the required patient enrollment totals for both the treatment arm and the control arm, patient inclusion/exclusion criteria and protocol changes designed to enhance patient enrollment.
KOOL: 3.50 (-0.17)
Cesca Reports Data From Six CLI Compassionate Use Patients Treated With SurgWerks(TM) Procedures at Fortis Escorts Heart Institute in New Delhi
GlobeNewswire - Wed May 11, 5:00AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced the results of six late-stage critical limb ischemia (CLI) patients treated with its SurgWerks(TM)-CLI system on a compassionate use basis. In a six-month follow-up of the patients, they reported favorable outcomes in lifestyle and pain reduction. The procedures were conducted by Dr. Suhail Bukhari of the Fortis Escorts Heart Institute and Research Center in New Delhi, India.
KOOL: 3.50 (-0.17)
Cesca Therapeutics to Report Third Quarter Fiscal 2016 Results on May 12, 2016
GlobeNewswire - Mon May 09, 5:00PM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that it will report financial results for the fiscal third quarter ended March 31, 2016 and provide a status update to investors on Thursday, May 12, 2016.
KOOL: 3.50 (-0.17)
Cesca Therapeutics To Present A Poster At The 2016 Annual Meeting Of The European Society For Blood And Bone Marrow Transplantation
GlobeNewswire - Thu Mar 31, 5:05AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that the Company will present a poster titled "Volume Reduction and RBC Depletion of Apheresis Products for Transplant" at the 42 Annual Meeting of the European Society for Blood and Bone Marrow Transplantation (EBMT) to be held in Valencia, Spain on April 3 - 6, 2016.
KOOL: 3.50 (-0.17)
Cesca Therapeutics' Indian Subsidiary Expands Cord Blood Banking Services To Additional Hospitals In The Fortis Healthcare Network
GlobeNewswire - Wed Mar 30, 5:05AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that its wholly-owned subsidiary in India, TotipotentRX, has expanded its private cord blood banking services into several hospitals within the Fortis Healthcare network in South and West India.
KOOL: 3.50 (-0.17)
Cesca Therapeutics Appoints Vascular Surgery Expert Lars Norgren, M.D., Ph.D., to its Clinical Advisory Board
GlobeNewswire - Wed Mar 23, 5:05AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that Dr. Lars Norgren, MD, Ph.D has joined its Clinical Advisory Board.
KOOL: 3.50 (-0.17)
Cesca Therapeutics to Present at the ARM 4th Annual Cell & Gene Therapy Investor Day
GlobeNewswire - Wed Mar 16, 5:05AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that Mike Bruch, Cesca Therapeutics' Chief Financial Officer, will present at the Alliance for Regenerative Medicine's 4 Annual Cell & Gene Therapy Investor Day on March 22, 2016, which will be held at the Metropolitan Club in New York City.
KOOL: 3.50 (-0.17)
Cesca Therapeutics Appoints Dr. Xiaochun Xu, Chairman and CEO of Boyalife Group, to Board of Directors
GlobeNewswire - Thu Mar 10, 5:05AM CST
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that Dr Xiaochun Xu (44) has been appointed to the Company's Board of Directors.
KOOL: 3.50 (-0.17)
Cesca Therapeutics Announces 1-for-20 Reverse Split of Common Stock
GlobeNewswire - Fri Mar 04, 3:05PM CST
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, has amended its Certificate of Incorporation to reflect a 1-for-20 reverse stock split effective 5:00pm PST on March 4, 2016.
KOOL: 3.50 (-0.17)
Texas Stem Cell Enters Into an Agreement With Cesca Therapeutics for Use of AutoXpress(R) Technology for Cord Blood Processing
GlobeNewswire - Tue Feb 09, 5:00AM CST
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that Texas Stem Cell has committed to utilizing Cesca's AutoXpress(R) AXP technology for its cord blood banking business. The AXP platform includes a 'smart' processing device and sterile disposable that automatically concentrates the stem cells from a cord blood unit in less than one hour and delivers them directly into Cesca's patented sample bag which is optimized for cryopreservation and storage. Cesca's AXP technology is widely used in cord blood banks around the world and has been referenced in dozens of clinical publications. Recently, clinical focus on cord blood has expanded due to the emergence of protocols enabling the expansion of cord blood cells in vitro, for subsequent therapeutic use in treatments for many forms of blood cancers including leukemia and lymphomas.
KOOL: 3.50 (-0.17)
Cell Therapy Industry: The Roads to Commercial Success
ACCESSWIRE - Wed Feb 03, 8:15AM CST
REDONDO BEACH, CA / ACCESSWIRE / February 3, 2016 / A recent panel discussion at the Alliance for Regenerative Medicine State of the Industry Briefing (associated with Biotech Showcase 2016 in San Francisco) raised the issue of bio-manufacturing scale up for cell therapies as a great need for continued development (see webcast here: http://alliancerm.org/event/regenerative-medi...-briefing). Among representatives of large pharmaceutical companies, or biotech companies partnered for development with large pharmaceutical companies, there was a general consensus that scaling up manufacturing for production of cell therapeutics was still a work in progress, and after nearly a decade of investment, more expertise and new technologies were required prior to commercialization.
KOOL: 3.50 (-0.17), MESO: 7.07 (+0.16), PFE: 35.29 (-0.02), CLLS: 29.48 (-1.53), NVS: 78.94 (-1.57)
